Results 181 to 190 of about 929,810 (294)
A Mixed Methods Pilot Study to Evaluate User Engagement with MedMicroMaps: A Novel Interactive E-learning Tool for Medical Microbiology. [PDF]
Harrington J.
europepmc +1 more source
Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin +3 more
wiley +1 more source
Ketaki Niranjan Pathak, Shital Shrikant Ghogale Department of Microbiology, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed University) (SIU), Pune, Maharashtra, IndiaCorrespondence: Ketaki Niranjan Pathak, Department of ...
Pathak KN, Ghogale SS
doaj
Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen +13 more
wiley +1 more source
Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack +25 more
wiley +1 more source
ABSTRACT Mycosis fungoides (MF) is a rare extranodal T‐cell lymphoma with primary cutaneous involvement. While it is the most common primary skin lymphoma, large‐scale real‐world data defining survival benchmarks and the prognostic significance of specific nodal sites remain limited.
Charalampos Filippatos +4 more
wiley +1 more source

